Research and Markets (http://www.researchandmarkets.com/research/cgkhnl/spinal_muscular)
has announced the addition of the "Spinal
Muscular Atrophy (SMA) - Pipeline Review, H1 2014" report to
'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2014', provides an
overview of the indication's therapeutic pipeline. This report provides
information on the therapeutic development for Spinal Muscular Atrophy
(SMA) , complete with latest updates, and special features on late-stage
and discontinued projects.
It also reviews key players involved in the therapeutic development for
Spinal Muscular Atrophy (SMA) . Spinal Muscular Atrophy (SMA) - Pipeline
Review, Half Year is built using data and information sourced from
Global Markets Direct's proprietary databases, Company/University
websites, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team.
- A snapshot of the global therapeutic scenario for Spinal Muscular
Atrophy (SMA) .
- A review of the Spinal Muscular Atrophy (SMA) products under
development by companies and universities/research institutes based on
information derived from company and industry-pecific sources.
- Coverage of products based on various stages of development ranging
from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
- Coverage of the Spinal Muscular Atrophy (SMA) pipeline on the basis of
route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Key Topics Covered:
Spinal Muscular Atrophy (SMA) Overview
Late Stage Products
Clinical Stage Products
Early Stage Products
olesoxime - Drug Profile
valproate sodium + [levocarnitine] - Drug Profile
ISIS-SMNRx - Drug Profile
sodium phenylbutyrate - Drug Profile
PF-06687859 - Drug Profile
SMN-2 - Drug Profile
MotorGraft - Drug Profile
AAV9-SMN Gene Therapy - Drug Profile
Motor Neuron Precursor Cells - Drug Profile
PTK-SMA-2 - Drug Profile
NXD-30001 - Drug Profile
DNA Oligonucleotides For Spinal Muscular Atrophy - Drug Profile
RE-003 - Drug Profile
fasudil - Drug Profile
Drug for Spinal Muscular Atrophy - Drug Profile
ND-602 - Drug Profile
RNase H-Active Antisense Oligos - Drug Profile
Indoprofren Analog - Drug Profile
Agrin Biologic For SMA - Drug Profile
Drugs for Motor Neuron Diseases - Drug Profile
PMO-25 - Drug Profile
INT-41 - Drug Profile
Antisense Molecules - Drug Profile
Featured News & Press Releases
F. Hoffmann-La Roche Ltd.
Isis Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
Nexgenix Pharmaceuticals, LLC
California Stem Cell, Inc.
Cellular Biomedicine Group, Inc.
For more information visit http://www.researchandmarkets.com/research/cgkhnl/spinal_muscular
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To NFVZone's Homepage ]